OncoScreen 001

Clinical Trial Title Pilot Study of OncoScreen, a Novel In Vitro Pharmacophenotyping Assay for Breast and Ovarian Cancers
Trial Status Open to Enrollment
Start Date 01/26/2023
Location hospitals
Trial Type Cancer - Adult Oncology
Specific Condition Breast and Ovarian Cancers
Description
Eligibility Criteria

Screening for eligibility: study investigators will work with study coordinators to screen their own patients for potential inclusion in this study.

Inclusion Criteria:

  • 1. Adults over 18 years of age with HER2+, newly diagnosed, previously untreated breast cancer >2 cm in diameter (n=10) requiring neoadjuvant therapy.
    OR
  • 2. Adults over 18 years of age with triple negative, newly diagnosed, previously untreated breast cancer >2 cm in diameter (n=10) requiring neoadjuvant therapy.
    OR
  • 3. Adults over 18 years of age with newly diagnosed, previously untreated, presumed high grade ovarian, fallopian tube or primary peritoneal cancer with peritoneal metastases (n=10) requiring neoadjuvant therapy. 

Exclusion Criteria: 

  • Patients with prior history of cancer within the last 5 years.

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.
IRB Number Central IRB
Notes
Principal Investigator Nathalie Johnson, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail oncologyresearch@lhs.org